The Trump administration has laid out a comprehensive health agenda, building on previous efforts while introducing significant new directions. With a focus spanning from patient access to experimental treatments to a major overhaul of the nation’s food systems, the approach aims for broad impact on American well-being.
During his initial presidency, Donald Trump signed the ‘Right To Try’ legislation, which granted terminally ill patients access to experimental treatments. His administration also launched Operation Warp Speed, a public-private partnership credited with accelerating the development and distribution of COVID-19 vaccines and therapeutics. Further, President Trump issued an executive order affirming the U.S. government’s policy to protect patients with pre-existing conditions. An additional executive order was signed to address kidney disease by promoting more transplants and improving treatment options. The administration also increased funding for Alzheimer’s research by $1 billion.
Looking ahead to a potential second term beginning in February 2025, Donald Trump appointed Robert F. Kennedy Jr. as the Secretary of Health and Human Services (HHS). Together, Trump and Kennedy established the ‘Make America Healthy Again’ (MAHA) Commission. This commission is tasked with investigating the root causes of chronic diseases, with a particular focus on those affecting children.
Under the leadership of HHS Secretary Kennedy, the MAHA initiative is focusing on reforming food and health systems. Its goal is to combat chronic diseases by directly addressing chemicals, pollutants, and additives present in food and promoting healthier dietary practices. As a tangible step, the HHS has announced plans under MAHA to phase out synthetic petroleum-based food dyes from the food supply by the end of 2026.
Beyond MAHA, the Trump-Kennedy administration has proposed significant reforms to the Head Start program. These changes aim to expand access and reduce regulatory burdens, with $2.2 billion in savings slated for reinvestment into the program, potentially preserving or expanding 236,000 slots. New policies have also been enacted by the FDA to prevent conflicts of interest on advisory committees, specifically limiting participation from individuals affiliated with regulated companies and prioritizing input from patients and caregivers. Furthermore, the administration has advanced policies aimed at lowering prescription drug prices for Americans.